Generic Name and Formulations:
Cabergoline 0.5mg; scored tabs.
Various generic manufacturers
Indications for Cabergoline:
Hyperprolactinemic disorders, either idiopathic or due to pituitary tumors.
Initially 0.25mg twice weekly. Dose may be increased at 4-week intervals by 0.25mg twice weekly. Max: 1mg twice weekly.
Uncontrolled hypertension. Sensitivity to ergot alkaloids.
Not for pregnancy-induced hypertension or postpartum lactation inhibition or suppression. Respiratory or cardiac disease due to fibrosis. Hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent dopamine D2 antagonists (eg, phenothiazines, butyrophenones, thioxanthines, metoclopramide): not recommended. Hypotension may be potentiated by antihypertensives.
GI upset, dizziness, fatigue, postural hypotension, nervousness, breast pain, dysmenorrhea, vision abnormalities; rare: fibrosis, valvulopathy.
Formerly known under the brand name Dostinex.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|